RU2516340C2 - Ускоренный способ очистки для получения капсульных полисахаридов streptococcus pneumoniae - Google Patents
Ускоренный способ очистки для получения капсульных полисахаридов streptococcus pneumoniae Download PDFInfo
- Publication number
- RU2516340C2 RU2516340C2 RU2009135485/10A RU2009135485A RU2516340C2 RU 2516340 C2 RU2516340 C2 RU 2516340C2 RU 2009135485/10 A RU2009135485/10 A RU 2009135485/10A RU 2009135485 A RU2009135485 A RU 2009135485A RU 2516340 C2 RU2516340 C2 RU 2516340C2
- Authority
- RU
- Russia
- Prior art keywords
- solution
- stage
- protein
- clarified
- retentate
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 381
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 381
- 150000004676 glycans Chemical class 0.000 title claims abstract description 374
- 238000000034 method Methods 0.000 title claims abstract description 172
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 39
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims abstract description 38
- 238000000746 purification Methods 0.000 title description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 202
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 202
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 115
- 239000012465 retentate Substances 0.000 claims abstract description 73
- 230000020477 pH reduction Effects 0.000 claims abstract description 65
- 238000001914 filtration Methods 0.000 claims abstract description 46
- 238000005119 centrifugation Methods 0.000 claims abstract description 31
- 238000013060 ultrafiltration and diafiltration Methods 0.000 claims abstract description 29
- 230000009089 cytolysis Effects 0.000 claims abstract description 14
- 239000002244 precipitate Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000012064 sodium phosphate buffer Substances 0.000 claims abstract description 7
- 229940124733 pneumococcal vaccine Drugs 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- 230000002101 lytic effect Effects 0.000 claims description 57
- 239000013592 cell lysate Substances 0.000 claims description 52
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 238000011026 diafiltration Methods 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 28
- 230000001580 bacterial effect Effects 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 16
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 229960003964 deoxycholic acid Drugs 0.000 claims description 13
- -1 lauryl imino Chemical group 0.000 claims description 12
- 108700004121 sarkosyl Proteins 0.000 claims description 10
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 10
- 238000005352 clarification Methods 0.000 claims description 7
- QRLIHCNZWBUPFS-UHFFFAOYSA-N C(C)O.OC=C Chemical compound C(C)O.OC=C QRLIHCNZWBUPFS-UHFFFAOYSA-N 0.000 claims description 5
- 229940009025 chenodeoxycholate Drugs 0.000 claims description 5
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 5
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims description 5
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 4
- 229940099352 cholate Drugs 0.000 claims description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 4
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 4
- DGABKXLVXPYZII-SIBKNCMHSA-M hyodeoxycholate Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-M 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 3
- XYYUAOIALFMRGY-UHFFFAOYSA-N 3-[2-carboxyethyl(dodecyl)amino]propanoic acid Chemical compound CCCCCCCCCCCCN(CCC(O)=O)CCC(O)=O XYYUAOIALFMRGY-UHFFFAOYSA-N 0.000 claims 2
- 229960001973 pneumococcal vaccines Drugs 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 28
- 239000006166 lysate Substances 0.000 abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 238000012986 modification Methods 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 229910052799 carbon Inorganic materials 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 239000013049 sediment Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 57
- 229940009976 deoxycholate Drugs 0.000 description 35
- 235000010633 broth Nutrition 0.000 description 34
- 238000004140 cleaning Methods 0.000 description 32
- 239000012535 impurity Substances 0.000 description 27
- 239000003599 detergent Substances 0.000 description 16
- 239000003245 coal Substances 0.000 description 14
- 230000002255 enzymatic effect Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 101150082581 lytA gene Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 230000002934 lysing effect Effects 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229940071204 lauryl sarcosinate Drugs 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QPRDKAJJYCDOFV-UHFFFAOYSA-N CCCCCCCCCCCCOC(=O)CCNCCC(O)=O Chemical compound CCCCCCCCCCCCOC(=O)CCNCCC(O)=O QPRDKAJJYCDOFV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89661607P | 2007-03-23 | 2007-03-23 | |
| US60/896,616 | 2007-03-23 | ||
| PCT/US2008/057688 WO2008118752A2 (en) | 2007-03-23 | 2008-03-20 | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009135485A RU2009135485A (ru) | 2011-04-27 |
| RU2516340C2 true RU2516340C2 (ru) | 2014-05-20 |
Family
ID=39712482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009135485/10A RU2516340C2 (ru) | 2007-03-23 | 2008-03-20 | Ускоренный способ очистки для получения капсульных полисахаридов streptococcus pneumoniae |
Country Status (29)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791744C1 (ru) * | 2022-08-18 | 2023-03-13 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Штамм Streptococcus pneumoniae серотип 19A |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE039169T2 (hu) * | 2007-03-23 | 2018-12-28 | Wyeth Llc | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| GB0818453D0 (en) * | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| PT2349520T (pt) * | 2008-10-27 | 2016-08-16 | Glaxosmithkline Biologicals Sa | Método de purificação para hidrato de carbono de estreptococos grupo a |
| EP2385981B1 (en) * | 2008-12-18 | 2019-09-04 | Wyeth LLC | Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon |
| WO2010080486A2 (en) * | 2008-12-18 | 2010-07-15 | Wyeth Llc | Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| WO2011041003A2 (en) | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
| US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| WO2011145108A2 (en) * | 2010-05-15 | 2011-11-24 | Serum Institute Of India Ltd. | Purification of capsular polysaccharides |
| BR112013024322B1 (pt) * | 2011-03-22 | 2020-04-22 | Serum Inst India Ltd | processo para preparação de polissacarídeos |
| CN102660601B (zh) * | 2012-04-17 | 2015-10-28 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| CN102660603B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 一种快速纯化细菌荚膜多糖的方法 |
| CN102660602B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| US9650411B2 (en) * | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
| CA2884241C (en) * | 2012-09-07 | 2018-11-20 | Sk Chemicals Co., Ltd. | Production method for capsular polysaccharide having pneumococcal serotype |
| CN104582718B (zh) | 2012-10-03 | 2017-10-24 | 诺华股份有限公司 | 免疫原性组合物 |
| US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
| US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
| US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
| US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
| US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
| US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
| CA2912765C (en) | 2013-07-12 | 2018-05-01 | Emd Millipore Corporation | A method of determining virus removal from a sample containing a target protein using activated carbon |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| FI3583947T3 (fi) * | 2014-01-21 | 2023-10-12 | Pfizer | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| PL3244917T3 (pl) | 2015-01-15 | 2023-07-17 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom |
| KR102143534B1 (ko) * | 2015-05-04 | 2020-08-12 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| HK1249149A1 (zh) * | 2015-06-18 | 2018-10-26 | 一般财团法人阪大微生物病研究会 | 肺炎球菌补体依赖性杀菌能力测量方法 |
| KR20250058066A (ko) | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| CN105131139B (zh) * | 2015-07-31 | 2018-02-13 | 兰州生物制品研究所有限责任公司 | 一种肺炎链球菌荚膜多糖的纯化方法 |
| US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US11224652B2 (en) | 2016-08-05 | 2022-01-18 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP3493837B1 (en) | 2016-08-05 | 2022-08-31 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| IL267709B2 (en) | 2016-12-30 | 2025-04-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| CN110225757A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法 |
| CN110392690B (zh) | 2017-02-24 | 2024-01-30 | 默沙东有限责任公司 | 肺炎球菌缀合物疫苗制剂 |
| JP7680185B2 (ja) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| MX2019014829A (es) | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
| US10435433B2 (en) | 2017-07-05 | 2019-10-08 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| CN111065387B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| HUE068482T2 (hu) | 2017-09-07 | 2025-01-28 | Merck Sharp & Dohme Llc | Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban |
| US11395849B2 (en) | 2017-09-07 | 2022-07-26 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| CN107936128B (zh) * | 2017-11-22 | 2020-07-03 | 成都欧林生物科技股份有限公司 | 一种简便有效的细菌疫苗纯化方法 |
| EP3720483B1 (en) | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2019152921A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BR112020015696A2 (pt) | 2018-02-05 | 2020-12-08 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| WO2019212842A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| WO2019212846A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| EP4483896A3 (en) | 2018-07-04 | 2025-04-02 | Vaxcyte, Inc. | Improvements in immunogenic conjugates |
| WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| WO2020016322A1 (en) * | 2018-07-19 | 2020-01-23 | Glaxosmithkline Biologicals Sa | Processes for preparing dried polysaccharides |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| JP2022542316A (ja) | 2019-07-31 | 2022-09-30 | サノフィ パスツール インコーポレイテッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法 |
| US12473379B2 (en) * | 2019-09-06 | 2025-11-18 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| CN115362177A (zh) * | 2020-02-21 | 2022-11-18 | 辉瑞公司 | 糖类的纯化 |
| US20230227487A1 (en) * | 2020-06-12 | 2023-07-20 | Basf Se | Improved demineralization of fermentation broths and purification of fine chemicals such as oligosaccharides |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP7714690B2 (ja) | 2021-05-28 | 2025-07-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| JP2025508749A (ja) | 2022-01-13 | 2025-04-10 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| GB2614916A (en) | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| US20260130987A1 (en) | 2022-10-19 | 2026-05-14 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN120513083A (zh) | 2022-12-01 | 2025-08-19 | 辉瑞大药厂 | 肺炎链球菌缀合物疫苗制剂 |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024246082A1 (en) | 2023-03-30 | 2025-10-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20252779A1 (es) | 2023-04-14 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20260294A1 (es) | 2023-05-18 | 2026-02-10 | Merck Sharp And Dohme Llc | Compuestos y formulaciones adyuvantes utiles en vacunas neumococicas |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002404A1 (en) * | 1977-11-28 | 1979-06-13 | Merck & Co. Inc. | Pneumococcal vaccine and a process for its preparation |
| WO1982001995A1 (fr) * | 1980-12-11 | 1982-06-24 | Merieux Inst | Procede de purification de polyosydes de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| US5623057A (en) * | 1991-01-28 | 1997-04-22 | Merck & Co., Inc. | Pneumococcal polysaccharide conjugate vaccine |
| RU2087156C1 (ru) * | 1995-06-22 | 1997-08-20 | Леонид Николаевич Падюков | Вакцина против пневмококковой инфекции |
| EP1401489A2 (en) * | 2001-06-20 | 2004-03-31 | Chiron SRL. | Capsular polysaccharide solubilisation and combination vaccines |
| EP1762245A2 (en) * | 1998-12-29 | 2007-03-14 | Connaught Laboratories | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2861695D1 (en) | 1977-11-07 | 1982-04-29 | Ciba Geigy Ag | Process for the manufacture of fluorinated cationic compounds and their use as surfactants |
| US4221906A (en) * | 1979-03-19 | 1980-09-09 | American Cyanamid Company | Stabilization of pneumococcal polysaccharides |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| JPS6170994A (ja) * | 1984-09-14 | 1986-04-11 | Daikin Ind Ltd | 環状（１→２）−β−Ｄ−グルカンの製法 |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5714354A (en) * | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
| JP4435413B2 (ja) * | 1997-12-23 | 2010-03-17 | バクスター・ヘルスケヤー・ソシエテ・アノニム | ワクチンとしてまたは結合体ワクチンとしてタンパク質に連結して使用するための細菌莢膜多糖の抽出および単離法 |
| GB0108079D0 (en) * | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| PL1866342T3 (pl) * | 2005-04-08 | 2019-04-30 | Wyeth Llc | Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH |
| IL308456A (en) * | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| HUE039169T2 (hu) * | 2007-03-23 | 2018-12-28 | Wyeth Llc | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
-
2008
- 2008-03-20 HU HUE11194173A patent/HUE039169T2/hu unknown
- 2008-03-20 HU HUE18177128A patent/HUE059085T2/hu unknown
- 2008-03-20 WO PCT/US2008/057688 patent/WO2008118752A2/en not_active Ceased
- 2008-03-20 PT PT87325924T patent/PT2129693T/pt unknown
- 2008-03-20 UA UAA200909741A patent/UA99278C2/ru unknown
- 2008-03-20 RU RU2009135485/10A patent/RU2516340C2/ru active
- 2008-03-20 PL PL18177128.8T patent/PL3406635T3/pl unknown
- 2008-03-20 KR KR1020097021976A patent/KR101500771B1/ko active Active
- 2008-03-20 EP EP08732592.4A patent/EP2129693B1/en active Active
- 2008-03-20 BR BRPI0809212A patent/BRPI0809212B8/pt active IP Right Grant
- 2008-03-20 PT PT181771288T patent/PT3406635T/pt unknown
- 2008-03-20 PT PT111941738T patent/PT2436700T/pt unknown
- 2008-03-20 US US12/052,525 patent/US8652480B2/en active Active
- 2008-03-20 DK DK08732592.4T patent/DK2129693T3/en active
- 2008-03-20 NZ NZ580134A patent/NZ580134A/en unknown
- 2008-03-20 EP EP11194173.8A patent/EP2436700B8/en active Active
- 2008-03-20 EP EP18177128.8A patent/EP3406635B1/en active Active
- 2008-03-20 MY MYPI20093908 patent/MY150927A/en unknown
- 2008-03-20 ES ES08732592.4T patent/ES2614249T3/es active Active
- 2008-03-20 DK DK18177128.8T patent/DK3406635T3/da active
- 2008-03-20 MX MX2009010221A patent/MX2009010221A/es active IP Right Grant
- 2008-03-20 HU HUE08732592A patent/HUE031567T2/hu unknown
- 2008-03-20 CN CN200880012946.2A patent/CN101663327B/zh active Active
- 2008-03-20 AU AU2008231041A patent/AU2008231041B2/en active Active
- 2008-03-20 SI SI200831741A patent/SI2129693T1/sl unknown
- 2008-03-20 KR KR1020157002150A patent/KR20150021127A/ko not_active Ceased
- 2008-03-20 JP JP2009554744A patent/JP5688902B2/ja active Active
- 2008-03-20 SI SI200832196T patent/SI3406635T1/sl unknown
- 2008-03-20 PL PL11194173T patent/PL2436700T3/pl unknown
- 2008-03-20 PL PL08732592T patent/PL2129693T3/pl unknown
- 2008-03-20 SI SI200831984T patent/SI2436700T1/sl unknown
- 2008-03-20 DK DK11194173.8T patent/DK2436700T5/en active
- 2008-03-20 CA CA2681570A patent/CA2681570C/en active Active
- 2008-03-20 CL CL200800831A patent/CL2008000831A1/es unknown
- 2008-03-20 ES ES11194173.8T patent/ES2677353T3/es active Active
- 2008-03-20 ES ES18177128T patent/ES2922132T3/es active Active
-
2009
- 2009-09-17 HN HN2009001965A patent/HN2009001965A/es unknown
- 2009-09-21 NI NI200900172A patent/NI200900172A/es unknown
- 2009-09-21 GT GT200900249A patent/GT200900249A/es unknown
- 2009-09-22 IL IL201106A patent/IL201106A/en active IP Right Grant
- 2009-09-22 ZA ZA200906625A patent/ZA200906625B/xx unknown
- 2009-09-23 CR CR11041A patent/CR11041A/es unknown
- 2009-09-23 EC EC2009009652A patent/ECSP099652A/es unknown
- 2009-10-20 CO CO09117278A patent/CO6251324A2/es active IP Right Grant
-
2014
- 2014-01-24 US US14/163,863 patent/US8999697B2/en active Active
-
2015
- 2015-01-27 JP JP2015013167A patent/JP2015143225A/ja not_active Withdrawn
- 2015-02-27 US US14/633,141 patent/US9675681B2/en active Active
-
2017
- 2017-03-23 JP JP2017056848A patent/JP6825950B2/ja active Active
- 2017-08-08 CL CL2017002029A patent/CL2017002029A1/es unknown
-
2018
- 2018-11-06 JP JP2018208647A patent/JP2019048844A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014532A patent/JP6872649B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0002404A1 (en) * | 1977-11-28 | 1979-06-13 | Merck & Co. Inc. | Pneumococcal vaccine and a process for its preparation |
| WO1982001995A1 (fr) * | 1980-12-11 | 1982-06-24 | Merieux Inst | Procede de purification de polyosydes de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| US5623057A (en) * | 1991-01-28 | 1997-04-22 | Merck & Co., Inc. | Pneumococcal polysaccharide conjugate vaccine |
| RU2087156C1 (ru) * | 1995-06-22 | 1997-08-20 | Леонид Николаевич Падюков | Вакцина против пневмококковой инфекции |
| EP1762245A2 (en) * | 1998-12-29 | 2007-03-14 | Connaught Laboratories | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| EP1401489A2 (en) * | 2001-06-20 | 2004-03-31 | Chiron SRL. | Capsular polysaccharide solubilisation and combination vaccines |
Non-Patent Citations (1)
| Title |
|---|
| GONСALVES V.M. ET AL. "Purification of capsular polysaccharide from Streptococcus pneumoniae serotype 23F by a procedure suitable for scale-up", Biotechnol Appl Biochem., 2003 v.37, N 3, pp. 283-287. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816593C1 (ru) * | 2020-02-21 | 2024-04-02 | Пфайзер Инк. | Очистка сахаридов |
| RU2791744C1 (ru) * | 2022-08-18 | 2023-03-13 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Штамм Streptococcus pneumoniae серотип 19A |
| RU2804137C1 (ru) * | 2022-08-18 | 2023-09-26 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Штамм Streptococcus pneumoniae серотип 19F |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101663327B (zh) | 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法 | |
| JP2010521972A5 (cg-RX-API-DMAC10.html) | ||
| RU2524436C2 (ru) | Способ получения жидкой фракции, содержащей изолированные высокомолекулярные капсульные полисахариды streptococcus pneumoniae, и жидкая фракция, полученная таким способом | |
| CN102660602B (zh) | 快速纯化细菌荚膜多糖的方法 | |
| US20260102479A1 (en) | Method for the purification of capsular polysaccharides | |
| HK1141815B (en) | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |